However, anti-IL-22/anti-CD160 co-therapy (or any other immunosuppressive immunotherapy) during CDI could ultimately induce an opposite effect, as excessive dampening of mucosal immune mechanisms could actually promote epithelial damage and C. difficile colonization. The gene discussed is IL22; the disease is clostridium difficile infection.